Abstract:Background Response Evaluation Criteria in Solid Tumours (RECIST) is the most widely acceptable assessment tool for assessing tumour response. However, volumetric evaluation (VE) was shown to be even more accurate than was RECIST in recent studies. Methods VE of liver metastases from patients with metastatic colorectal cancer (mCRC) was performed by manual contouring of all liver metastases on computed tomography (CT) images of 5 mm slice thickness on the Eclipse Treatment Planning System at baseline and after chemotherapy with FOLFOX4 (n = 18) with or without cetuximab (n = 14) on 41 pairs of CT images in 32 patients treated at the Queen Mary Hospital from January 2008 to December 2010. The aggregate tumour volumes were then compared with the baseline for tumour response. Best objective response (OR) by use of VE (PD, >73% compared with nadir; SD, between PD and PR; PR <65% compared with nadir; CR, complete disappearance) was defined according to previous reports. Cohen kappa was used to compare OR based on VE, RECIST, and Independent Radiologist Review Committee (IRRC). Pearson correlation was calculated for association between VE and RECIST after cubic root transformation of the aggregate tumour volumes. Logistic regression was done for any clinical and radiological factors, accounting for the difference in OR between VE and RECIST. Findings OR by VE did not match with that by use of RECIST in six pairs of comparisons. However, VE showed good agreement with RECIST ( κ = 0.755 ) and also better agreement with IRRC than did RECIST ( κ = 0.547 and κ = 0.462 , respectively). Pearson correlation showed an excellent correlation between VE and RECIST ( r 2 = 0.968 , p < 0.001). Subgroup analysis showed better agreement for enlarging lesions than for shrinking lesions ( r 2 = 0.974 and r 2 = 0.887 , respectively). No factor was predictive of the difference in OR between VE and RECIST. Interpretation VE showed good agreement with RECIST in OR evaluation. It might be a better method than RECIST when evaluating conglomerate matted liver metastases. The authors declared no conflicts of interest. Response Evaluation Criteria in Solid Tumours (RECIST) is the most widely acceptable assessment tool for assessing tumour response. However, volumetric evaluation (VE) was shown to be even more accurate than was RECIST in recent studies. VE of liver metastases from patients with metastatic colorectal cancer (mCRC) was performed by manual contouring of all liver metastases on computed tomography (CT) images of 5 mm slice thickness on the Eclipse Treatment Planning System at baseline and after chemotherapy with FOLFOX4 (n = 18) with or without cetuximab (n = 14) on 41 pairs of CT images in 32 patients treated at the Queen Mary Hospital from January 2008 to December 2010. The aggregate tumour volumes were then compared with the baseline for tumour response. Best objective response (OR) by use of VE (PD, >73% compared with nadir; SD, between PD and PR; PR <65% compared with nadir; CR, complete disappearance) was defined according to previous reports. Cohen kappa was used to compare OR based on VE, RECIST, and Independent Radiologist Review Committee (IRRC). Pearson correlation was calculated for association between VE and RECIST after cubic root transformation of the aggregate tumour volumes. Logistic regression was done for any clinical and radiological factors, accounting for the difference in OR between VE and RECIST. OR by VE did not match with that by use of RECIST in six pairs of comparisons. However, VE showed good agreement with RECIST ( κ = 0.755 ) and also better agreement with IRRC than did RECIST ( κ = 0.547 and κ = 0.462 , respectively). Pearson correlation showed an excellent correlation between VE and RECIST ( r 2 = 0.968 , p < 0.001). Subgroup analysis showed better agreement for enlarging lesions than for shrinking lesions ( r 2 = 0.974 and r 2 = 0.887 , respectively). No factor was predictive of the difference in OR between VE and RECIST. VE showed good agreement with RECIST in OR evaluation. It might be a better method than RECIST when evaluating conglomerate matted liver metastases. The authors declared no conflicts of interest.

<i>Implementing Real-World RECIST-based Tumor Response Assessment in Patients With Metastatic Non-small Cell Lung Cancer</i> Comment

Feasibility of RECIST-based Real-World Tumor Response Assessment in Metastatic Non-Small Cell Lung Cancer Patients.

Transient spinal cord ischemia induces temporary hypersensitivity of dorsal horn wide dynamic range neurons to myelinated, but not unmyelinated, fiber input.

Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients

Use of RECIST criteria in evaluation of therapeutic response in breast cancer metastases:with comparison of WHO criteria

Effectiveness and Safety of Camrelizumab in Inoperable or Advanced Non-Small Cell Lung Cancer Patients: a Multicenter Real-World Retrospective Observational Study (CTONG2004-ADV).

Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations

Radiomics for the Prediction of Pathological Complete Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Observational Trial.

Gabapentin-Induced Worsening of Neuropsychiatric Symptoms in Dementia with Lewy Bodies: Case Reports

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

Occupational hearing conservation.

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

A Narrative Review: Depth of Response As a Predictor of the Long-Term Outcomes for Solid Tumors

Real-World Data and Evidence in Lung Cancer: A Review of Recent Developments

Psychotropic drugs and fertility.

Abstract 3844: Clinical implications of mixed response on prognosis of non-small cell lung cancer (NSCLC) patients treated with Immunotherapy

Abstract 2551: Harness the power of real-world-data for oncology target and biomarker research: A case study by applying clinic-genomics data for 2,659 lung cancer patients and beyond

Abstract 7530: Harmonization radiomics models to predict tumor response in non-small cell lung cancer (NSCLC) patients treated with immunotherapy

Radiomics in predicting treatment response in non-small-cell lung cancer: current status, challenges and future perspectives

AOSOP4 Comparison of Volumetric Evaluation for Tumour Response with RECIST in Metastatic Colorectal Cancer with Liver Metastases Only

On The Selective Conductivity Exhibited By Certain Polarising Substances